For example, CRISPR/Cas9 gene editing was used to generate a vimentin red fluorescent protein (RFP) fusion reporter in a non-small cell lung cancer (NSCLC) cell line for real-time tracking of EMT status, resulting in the discovery of two EMT inhibitors [52]. Here, VIM is linked to non-small cell lung carcinoma.